*Remission is based on CR, ORR and PR. CR is defined in the SmPC as complete remission.
UK-VNCCLL-220184 | May 2022
UK-VNCCLL-230003. Date of Preparation: March 2023.
Patient guide for VEN in 1L
UK-VNCCLL-230215
Patient guide for VEN in R/R
UK-VNCCLL-230216
Patient guide for VEN in all lines
UK-VNCCLL-230304
A guide to completing treatment with VENCLYXTO
UK-VNCCLL-230048
1L=First line; CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; R/R=relapsed/refractory; SmPC=Summary of product characteristics; VEN=VENCLYXTO.
References
- VENCLYXTO Summary of Product Characteristics.
- Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
- Fischer K et al. N Engl J Med. 2019; 380: 2225–36.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected].
You are strongly advised to read the prescribing information and summary of product characteristics to evaluate patient suitability for Venclyxto.
UK-VNCCLL-230374. Date of preparation: September 2023.
